Roman Kasianov
Covers AI in drug discovery, digital pathology, and translational R&D, editor of "Where Tech Meets Bio"; oversees company profiles, partnerships, and core operations at BiopharmaTrend.
Recent articles from Roman
Lilly Taps Insilico Medicine's AI in $100M Drug Discovery Collaboration
Insilico Medicine has entered a research and licensing collaboration with Eli Lilly, expanding their existing partnership to jointly discover novel therapeutics using Insilico’s Pharma.AI platform. The collaboration builds on a prior software licensing agreement signed in 2023, under which Lilly …
Insilico Medicine Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI
On November 7, 2025 at BIO-Europe, Insilico Medicine disclosed eight oral small-molecule programs for cardiometabolic diseases discovered with its Pharma.AI platform. The portfolio spans lead identification to IND-enabling and targets GLP-1R, GIPR, dual amylin/calcitonin receptors (DACRA), APJ, Lp(a), NLRP3, and …
Recursion Completes Whole-Genome Microglia Map With Roche and Genentech
Recursion announces the acceptance of its whole-genome Microglia Map by Roche and Genentech, marking the culmination of a three-year collaboration focused on decoding microglial cell biology.
The milestone triggered a $30 million payment to Recursion, bringing total cash inflows from …
Flagship's New AI Covalent Chemistry Startup; $50M Commitment and Pfizer Program
Flagship Pioneering announced Expedition Medicines after three years of internal development, committing $50 million to scale a quantum-chemistry-driven generative platform for covalent small-molecule discovery, with programs in oncology, immunology, and other well-defined diseases. Expedition, founded in 2022, has begun …
Iambic’s AI-Designed Cancer Drug Shows Early Clinical Activity
Iambic Therapeutics presented new data from its ongoing Phase 1/1b trial of IAM1363 at the 2025 ESMO Congress, showing anti-tumor activity in heavily pretreated patients with HER2-driven cancers, including those previously treated with T-DXd and tucatinib. The AI-designed small molecule …
AstraZeneca and AI-Powered Immune Mapping Company Immunai Sign Up To $85M IBD Target Agreement
Immunai has signed an agreement with AstraZeneca to develop a therapeutic target for inflammatory bowel disease (IBD), marking a shift from their existing oncology-focused collaboration started in 2022. The deal is valued at up to $85 million and grants …
Sanofi Licenses BenchSci’s Neurosymbolic AI for Global Preclinical R&D
Sanofi has signed a three-year license agreement with Toronto-based BenchSci to deploy the ASCEND platform across its global preclinical research teams. The partnership marks a move to embed neurosymbolic AI into core R&D operations, offering scientists and contractors at Sanofi …
AI Model Built on Transformer Architecture Maps 1,300 Mouse Brain Regions in Data-Driven Atlas
Researchers at UCSF and the Allen Institute have developed a transformer-based AI model CellTransformer that maps 1,300 brain regions and subregions in the mouse brain, including previously uncharted subregions. The model was applied to large-scale spatial transcriptomics datasets, results were …
AstraZeneca Signs $555 Million AI Deal For CRISPR Therapies
AstraZeneca agreed to a collaboration worth up to $555m in regulatory and commercial milestones with San Francisco–based Algen Biotechnologies, securing exclusive rights to develop and commercialise therapies from CRISPR gene-editing technology; AstraZeneca is not taking an equity stake. The …
Human Cells Edited at Megabase Scale With Bridge Recombinases
Researchers report in Science a genome-editing approach that rearranges long stretches of human DNA—insertions, deletions, and inversions—within regions up to about one megabase (with demonstrations of ~920 kb inversions and ~130 kb deletions), with reported insertion efficiencies up to 20% …